International Journal of Women's Health and Reproduction Sciences

Home Aim and Scope Instructions to Authors Editorial Policies Editorial Board Authorship Agreement Form Open Access and Copyright

Jan 2025, Vol 13, Issue 1

CURRENT ISSUE ARCHIVE AHEAD OF PRINT / ACCEPTED ARTICLE MOST VIEWED ARTICLES NEWS RELATED LINKS

Advanced Search

For Author's & Reviewer's

Committee on Publication
Ethics (COPE) Flowchart

Recommendations for the Conduct

COPE: Reviewers

World Association of Medical Editors(WAME)

EQUATOR Resources : Reviewers

Poll

How do you find the scientific quality of the published articles on our web site?

Very good

Good

Fair

Bad

Very bad

Original Article
The Early Versus Standard Administration of Cabergoline to Prevent Ovarian Hyperstimulation Syndrome in Patients With Polycystic Ovary Syndrome Undergoing ICSI cycles: A Randomized Clinical Trial
Roza Shahhosseini¹, Ashraf Moini^1,2,3, Nazanin Hajizadeh⁴, Ladan Kashani¹, Maryam Farid Mojtahedi¹, Farzaneh Alemohammad¹, Farah Ghasemi¹, Najmeh Zarei¹
¹Department of Gynecology and Obstetrics, Infertility Ward, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran ²Breast Disease Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran ³Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran ⁴Preventive Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
DOI: 10.15296/ijwhr.2024.6013 Viewed : 97 times Downloaded : 115 times. Keywords : Cabergoline, Polycystic ovary syndrome, Ovarian hyperstimulation syndrome, Drug administration schedule
Full Text(PDF) \| Related Articles
Abstract

Objectives: The effect of cabergoline on reducing the incidence rate of ovarian hyperstimulation syndrome (OHSS) has been confirmed by several studies. Currently, what is discussed in this regard is when cabergoline should be started to be most effective in reducing the occurrence and developing rates of OHSS. Methods and Materials: A clinical trial conducted at Arash Women’s Hospital from March to November 2023 included 200 infertile women with polycystic ovary syndrome (PCOS) at risk of OHSS during in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment. Participants were divided into two groups: the experimental group received cabergoline from the start of GnRH antagonist administration for 15 days, and the control group received cabergoline for eight days after oocyte trigger. Measurements of hematocrit (Hct) percentage, serum creatinine (Cr), sodium (Na), and potassium (K) levels, and abdominal circumference were taken three days after ovum pick-up. The study monitored patients until menstruation and focused on the occurrence and severity of OHSS as primary outcomes. Results: The data analysis showed that the two groups were comparable regarding basic characteristics. In the following, the OHSS rate in the early administration group was significantly lower than the control group (14% vs. 47%, P<0.001). In the study group, the severity of all OHSS cases was mild, while the control group reported a moderate severity of OHSS (P<0.001). Conclusions: Earlier initiation of cabergoline from the time of administration of the GnRH antagonist compared to its initiation from the day of oocyte triggering has more effectively reduced the rate and severity of OHSS and improved patient satisfaction. Trial Registration: The study was registered in the Iranian Registry of Clinical Trials on 2023-05-30 (identifier: IRCT20090526001952N16, https://www.irct.ir) during the recruitment phase.